Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma

MeSH terms

• Antibodies, Monoclonal / adverse effects*
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20 / immunology
• Antigens, Neoplasm / immunology
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Combined Modality Therapy / adverse effects
• Fatal Outcome
• Humans
• Immunophenotyping
• Immunotherapy / adverse effects*
• Lymphoma, Large B-Cell, Diffuse / drug therapy
• Lymphoma, Large B-Cell, Diffuse / radiotherapy
• Lymphoma, Large B-Cell, Diffuse / therapy*
• Lymphoma, Non-Hodgkin / drug therapy
• Lymphoma, Non-Hodgkin / radiotherapy
• Lymphoma, Non-Hodgkin / therapy*
• Lymphoma, T-Cell, Peripheral / etiology*
• Male
• Middle Aged
• Neoplasms, Second Primary / etiology*
• Rituximab